{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:51:39Z","timestamp":1767837099562,"version":"3.49.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,5]]},"DOI":"10.7759\/cureus.59687","type":"journal-article","created":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T23:51:15Z","timestamp":1714953075000},"source":"Crossref","is-referenced-by-count":2,"title":["Drug-Induced Liver Injury Due to Doxycycline: A Case Report and Review of Literature"],"prefix":"10.7759","author":[{"given":"Nikola","family":"Nikolajevic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milan","family":"Nikolajevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Pantic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bojan","family":"Korica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Kotseva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Alempijevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorde","family":"Jevtic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian I","family":"Madrid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Dumic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2021.10.035","article-title":"Drug-induced liver injury: pathogenesis, epidemiology, clinical features, and practical management","volume":"97","author":"Bj\u00f6rnsson HK","year":"2022","unstructured":"Bj\u00f6rnsson HK, Bj\u00f6rnsson ES. Drug-induced liver injury: pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med. 2022, 97:26-31. 10.1016\/j.ejim.2021.10.035","journal-title":"Eur J Intern Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13931","article-title":"The diagnosis and management of idiosyncratic drug-induced liver injury","volume":"39","author":"Hassan A","year":"2019","unstructured":"Hassan A, Fontana RJ. The diagnosis and management of idiosyncratic drug-induced liver injury. Liver Int. 2019, 39:31-41. 10.1111\/liv.13931","journal-title":"Liver Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15262","article-title":"Incidence and risk factors of drug-induced liver injury","volume":"42","author":"Li X","year":"2022","unstructured":"Li X, Tang J, Mao Y. Incidence and risk factors of drug-induced liver injury. Liver Int. 2022, 42:1999-2014. 10.1111\/liv.15262","journal-title":"Liver Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.12.040","article-title":"The evolving profile of idiosyncratic drug-induced liver injury","volume":"21","author":"Fontana RJ","year":"2023","unstructured":"Fontana RJ, Bjornsson ES, Reddy R, Andrade RJ. The evolving profile of idiosyncratic drug-induced liver injury. Clin Gastroenterol Hepatol. 2023, 21:2088-99. 10.1016\/j.cgh.2022.12.040","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18051018","article-title":"Drug-induced liver injury: cascade of events leading to cell death, apoptosis or necrosis","volume":"18","author":"Iorga A","year":"2017","unstructured":"Iorga A, Dara L, Kaplowitz N. Drug-induced liver injury: cascade of events leading to cell death, apoptosis or necrosis. Int J Mol Sci. 2017, 18:1018. 10.3390\/ijms18051018","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02133.x","article-title":"Acute and clinically relevant drug-induced liver injury: a population based case-control study","volume":"58","author":"de Abajo FJ","year":"2004","unstructured":"de Abajo FJ, Montero D, Madurga M, Garc\u00eda Rodr\u00edguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 2004, 58:71-80. 10.1111\/j.1365-2125.2004.02133.x","journal-title":"Br J Clin Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.02.006","article-title":"Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland","volume":"144","author":"Bj\u00f6rnsson ES","year":"2013","unstructured":"Bj\u00f6rnsson ES, Bergmann OM, Bj\u00f6rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013, 144:1419-25.e1-3; quiz e19-20. 10.1053\/j.gastro.2013.02.006","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.02.002","article-title":"Incidence and etiology of drug-induced liver injury in mainland China","volume":"156","author":"Shen T","year":"2019","unstructured":"Shen T, Liu Y, Shang J, et al.. Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology. 2019, 156:2230-41.e11. 10.1053\/j.gastro.2019.02.002","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2174\/1874467214666210210122628","article-title":"Minocycline and doxycycline: more than antibiotics","volume":"14","author":"Singh S","year":"2021","unstructured":"Singh S, Khanna D, Kalra S. Minocycline and doxycycline: more than antibiotics. Curr Mol Pharmacol. 2021, 14:1046-65. 10.2174\/1874467214666210210122628","journal-title":"Curr Mol Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-020-01188-y","article-title":"Immunomodulatory effect of doxycycline ameliorates systemic and pulmonary inflammation in a Murine polymicrobial sepsis model. Inflammation","volume":"43","author":"Patel A","year":"2020","unstructured":"Patel A, Khande H, Periasamy H, Mokale S. Immunomodulatory effect of doxycycline ameliorates systemic and pulmonary inflammation in a Murine polymicrobial sepsis model. Inflammation. Inflammation. 2020, 43:1035-43. 10.1007\/s10753-020-01188-y","journal-title":"Inflammation"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-051X.2005.00840.x","article-title":"Long-term treatment with sub-antimicrobial dose doxycycline has no antibacterial effect on intestinal flora","volume":"32","author":"Walker C","year":"2005","unstructured":"Walker C, Preshaw PM, Novak J, Hefti AF, Bradshaw M, Powala C. Long-term treatment with sub-antimicrobial dose doxycycline has no antibacterial effect on intestinal flora. J Clin Periodontol. 2005, 32:1163-9. 10.1111\/j.1600-051X.2005.00840.x","journal-title":"J Clin Periodontol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2007.00853.x","article-title":"Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study","volume":"32","author":"Heaton PC","year":"2007","unstructured":"Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. J Clin Pharm Ther. 2007, 32:483-7. 10.1111\/j.1365-2710.2007.00853.x","journal-title":"J Clin Pharm Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2017.1291719","article-title":"Drug-induced liver injury due to antibiotics","volume":"52","author":"Bj\u00f6rnsson ES","year":"2017","unstructured":"Bj\u00f6rnsson ES. Drug-induced liver injury due to antibiotics. Scand J Gastroenterol. 2017, 52:617-23. 10.1080\/00365521.2017.1291719","journal-title":"Scand J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001259","article-title":"CG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","author":"Chalasani NP","year":"2021","unstructured":"Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR. CG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2021, 116:878-98. 10.14309\/ajg.0000000000001259","journal-title":"Am J Gastroenterol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21324","article-title":"Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain","volume":"44","author":"Lucena MI","year":"2006","unstructured":"Lucena MI, Andrade RJ, Fern\u00e1ndez MC, et al.. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology. 2006, 44:850-6. 10.1002\/hep.21324","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840080327","article-title":"Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases","volume":"8","author":"Stricker BH","year":"1988","unstructured":"Stricker BH, Blok AP, Claas FH, Van Parys GE, Desmet VJ. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology. 1988, 8:599-606. 10.1002\/hep.1840080327","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.05.043","article-title":"Features of autoimmune hepatitis in patients with drug-induced liver injury","volume":"15","author":"de Boer YS","year":"2017","unstructured":"de Boer YS, Kosinski AS, Urban TJ, et al.. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol. 2017, 15:103-112.e2. 10.1016\/j.cgh.2016.05.043","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.11.036","article-title":"Identification and characterization of cefazolin-induced liver injury","volume":"13","author":"Alqahtani SA","year":"2015","unstructured":"Alqahtani SA, Kleiner DE, Ghabril M, Gu J, Hoofnagle JH, Rockey DC. Identification and characterization of cefazolin-induced liver injury. Clin Gastroenterol Hepatol. 2015, 13:1328-36.e2. 10.1016\/j.cgh.2014.11.036","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-022-01397-5","article-title":"A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data","volume":"44","author":"Wei C","year":"2022","unstructured":"Wei C, Liu Y, Jiang A, Wu B. A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data. Int J Clin Pharm. 2022, 44:709-16. 10.1007\/s11096-022-01397-5","journal-title":"Int J Clin Pharm"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.761167","article-title":"Real-world data of tigecycline-associated drug-induced liver injury among patients in China: a 3-year retrospective study as assessed by the updated RUCAM","volume":"12","author":"Shi X","year":"2021","unstructured":"Shi X, Zuo C, Yu L, Lao D, Li X, Xu Q, Lv Q. Real-world data of tigecycline-associated drug-induced liver injury among patients in China: a 3-year retrospective study as assessed by the updated RUCAM. Front Pharmacol. 2021, 12:761167. 10.3389\/fphar.2021.761167","journal-title":"Front Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2022.04.024","article-title":"Prevalence and risk factors of tigecycline-induced liver injury: a\u00a0multicenter retrospective study","volume":"120","author":"Yu Z","year":"2022","unstructured":"Yu Z, Zhao Y, Jin J, Zhu J, Yu L, Han G. Prevalence and risk factors of tigecycline-induced liver injury: a\u00a0multicenter retrospective study. Int J Infect Dis. 2022, 120:59-64. 10.1016\/j.ijid.2022.04.024","journal-title":"Int J Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07258-w","article-title":"A case report of drug-induced liver injury after tigecycline administration: histopathological evidence and a probable causality grading as assessed by the updated RUCAM diagnostic scale","volume":"22","author":"Shi X","year":"2022","unstructured":"Shi X, Lao D, Xu Q, Li X, Lv Q. A case report of drug-induced liver injury after tigecycline administration: histopathological evidence and a probable causality grading as assessed by the updated RUCAM diagnostic scale. BMC Infect Dis. 2022, 22:368. 10.1186\/s12879-022-07258-w","journal-title":"BMC Infect Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.02.019","article-title":"Clinical and histopathologic features of fluoroquinolone-induced liver injury","volume":"9","author":"Orman ES","year":"2011","unstructured":"Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J, Kleiner DE, Hayashi PH. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol. 2011, 9:517-23.e3. 10.1016\/j.cgh.2011.02.019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2007.03330.x","article-title":"The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury","volume":"25","author":"Bj\u00f6rnsson E","year":"2007","unstructured":"Bj\u00f6rnsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther. 2007, 25:1411-21. 10.1111\/j.1365-2036.2007.03330.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.07.054","article-title":"Clinical and histologic features of azithromycin-induced liver injury","volume":"13","author":"Martinez MA","year":"2015","unstructured":"Martinez MA, Vuppalanchi R, Fontana RJ, et al.. Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol. 2015, 13:369-76.e3. 10.1016\/j.cgh.2014.07.054","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20800","article-title":"Outcome and prognostic markers in severe drug-induced liver disease","volume":"42","author":"Bj\u00f6rnsson E","year":"2005","unstructured":"Bj\u00f6rnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005, 42:481-9. 10.1002\/hep.20800","journal-title":"Hepatology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.12659%2FAJCR.911393","article-title":"Idiosyncratic drug-induced liver injury due to ciprofloxacin: a report of two cases and review of the literature","volume":"19","author":"Radovanovic M","year":"2018","unstructured":"Radovanovic M, Dushenkovska T, Cvorovic I, et al.. Idiosyncratic drug-induced liver injury due to ciprofloxacin: a report of two cases and review of the literature. Am J Case Rep. 2018, 19:1152-61. 10.12659%2FAJCR.911393","journal-title":"Am J Case Rep"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-021-01475-7","article-title":"Doxycycline-induced cholestatic liver injury","volume":"14","author":"Varma S","year":"2021","unstructured":"Varma S, Nathanson J, Dowlatshahi M, Del Portillo A, Ramirez I, Garcia-Carrasquillo R. Doxycycline-induced cholestatic liver injury. Clin J Gastroenterol. 2021, 14:1503-10. 10.1007\/s12328-021-01475-7","journal-title":"Clin J Gastroenterol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1080\/17843286.1992.11718230","article-title":"Doxycycline and hepatotoxicity","volume":"47","author":"Lienart F","year":"1992","unstructured":"Lienart F, Morissens M, Jacobs P, Ducobu J. Doxycycline and hepatotoxicity. Acta Clin Belg. 1992, 47:205-8. 10.1080\/17843286.1992.11718230","journal-title":"Acta Clin Belg"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1999.00606.x","article-title":"Chronic intoxication by doxycycline use for more than 12 years","volume":"246","author":"Westermann GW","year":"1999","unstructured":"Westermann GW, B\u00f6hm M, Bonsmann G, Rahn KH, Kisters K. Chronic intoxication by doxycycline use for more than 12 years. J Intern Med. 1999, 246:591-2. 10.1046\/j.1365-2796.1999.00606.x","journal-title":"J Intern Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1177\/0009922814556982","article-title":"Fulminant liver failure presenting shortly after initiation of doxycycline: a case report","volume":"54","author":"Fish J","year":"2015","unstructured":"Fish J, Ingram D, Walkiewicz-Jedrzejczak D. Fulminant liver failure presenting shortly after initiation of doxycycline: a case report. Clin Pediatr (Phila). 2015, 54:904-6. 10.1177\/0009922814556982","journal-title":"Clin Pediatr (Phila)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.03.050","article-title":"Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury","volume":"147","author":"Robles-Diaz M","year":"2014","unstructured":"Robles-Diaz M, Lucena MI, Kaplowitz N, et al.. Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology. 2014, 147:109-18.e5. 10.1053\/j.gastro.2014.03.050","journal-title":"Gastroenterology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0105-0","article-title":"Drug-induced liver injury","volume":"5","author":"Andrade RJ","year":"2019","unstructured":"Andrade RJ, Chalasani N, Bj\u00f6rnsson ES, et al.. Drug-induced liver injury. Nat Rev Dis Primers. 2019, 5:58. 10.1038\/s41572-019-0105-0","journal-title":"Nat Rev Dis Primers"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.12701\/yujm.2019.00297","article-title":"Drug-induced liver injury","volume":"37","author":"Suh JI","year":"2020","unstructured":"Suh JI. Drug-induced liver injury. Yeungnam Univ J Med. 2020, 37:2-12. 10.12701\/yujm.2019.00297","journal-title":"Yeungnam Univ J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL clinical practice guidelines: drug-induced liver injury","volume":"70","year":"2019","unstructured":"EASL clinical practice guidelines. drug-induced liver injury. J Hepatol. 2019, 70:1222-61. 10.1016\/j.jhep.2019.02.014","journal-title":"J Hepatol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-020-02885-1","article-title":"Drug induced liver injury: an update","volume":"94","author":"Garcia-Cortes M","year":"2020","unstructured":"Garcia-Cortes M, Robles-Diaz M, Stephens C, Ortega-Alonso A, Lucena MI, Andrade RJ. Drug induced liver injury: an update. Arch Toxicol. 2020, 94:3381-407. 10.1007\/s00204-020-02885-1","journal-title":"Arch Toxicol"},{"key":"ref37","doi-asserted-by":"crossref","DOI":"10.3727\/105221617X15084371374138","article-title":"Acetaminophen toxicity: novel insights into mechanisms and future perspectives","volume":"18","author":"Ramachandran A","year":"2018","unstructured":"Ramachandran A, Jaeschke H. Acetaminophen toxicity: novel insights into mechanisms and future perspectives. Gene Expr. 2018, 18:19-30.","journal-title":"Gene Expr"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106348","article-title":"Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury","volume":"182","author":"Rodriguez-Diaz C","year":"2022","unstructured":"Rodriguez-Diaz C, Taminiau B, Garc\u00eda-Garc\u00eda A, et al.. Microbiota diversity in nonalcoholic fatty liver disease and in drug-induced liver injury. Pharmacol Res. 2022, 182:106348. 10.1016\/j.phrs.2022.106348","journal-title":"Pharmacol Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.972518","article-title":"Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: emerging role of gut microbiota dysbiosis","volume":"9","author":"Fu L","year":"2022","unstructured":"Fu L, Qian Y, Shang Z, Sun X, Kong X, Gao Y. Antibiotics enhancing drug-induced liver injury assessed for causality using Roussel Uclaf Causality Assessment Method: emerging role of gut microbiota dysbiosis. Front Med (Lausanne). 2022, 9:972518. 10.3389\/fmed.2022.972518","journal-title":"Front Med (Lausanne)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.hbpd.2023.06.008","article-title":"Contribution of gut microbiota to drug-induced liver injury","volume":"22","author":"Chu HK","year":"2023","unstructured":"Chu HK, Ai Y, Cheng ZL, Yang L, Hou XH. Contribution of gut microbiota to drug-induced liver injury. Hepatobiliary Pancreat Dis Int. 2023, 22:458-65. 10.1016\/j.hbpd.2023.06.008","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study","volume":"148","author":"Chalasani N","year":"2015","unstructured":"Chalasani N, Bonkovsky HL, Fontana R, et al.. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015, 148:1340-52.e7. 10.1053\/j.gastro.2015.03.006","journal-title":"Gastroenterology"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-021-01109-4","article-title":"Drug-induced liver injury: highlights and controversies in the recent literature","volume":"44","author":"Clinton JW","year":"2021","unstructured":"Clinton JW, Kiparizoska S, Aggarwal S, Woo S, Davis W, Lewis JH. Drug-induced liver injury: highlights and controversies in the recent literature. Drug Saf. 2021, 44:1125-49. 10.1007\/s40264-021-01109-4","journal-title":"Drug Saf"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001913","article-title":"Idiosyncratic drug-induced liver injury associated with and without drug reaction with eosinophilia and systemic symptoms","volume":"117","author":"Devarbhavi H","year":"2022","unstructured":"Devarbhavi H, Kurien SS, Raj S, Patil M, Gowda V, Kothari K, Singh R. Idiosyncratic drug-induced liver injury associated with and without drug reaction with eosinophilia and systemic symptoms. Am J Gastroenterol. 2022, 117:1709-13. 10.14309\/ajg.0000000000001913","journal-title":"Am J Gastroenterol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1159\/000119753","article-title":"Severe drug hypersensitivity reaction in a young woman treated with doxycycline","volume":"217","author":"Robles DT","year":"2008","unstructured":"Robles DT, Leonard JL, Compton N, et al.. Severe drug hypersensitivity reaction in a young woman treated with doxycycline. Dermatology. 2008, 217:23-6. 10.1159\/000119753","journal-title":"Dermatology"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.043","article-title":"Value of liver biopsy in the diagnosis of drug-induced liver injury","volume":"76","author":"Ahmad J","year":"2022","unstructured":"Ahmad J, Barnhart HX, Bonacini M, et al.. Value of liver biopsy in the diagnosis of drug-induced liver injury. J Hepatol. 2022, 76:1070-8. 10.1016\/j.jhep.2021.12.043","journal-title":"J Hepatol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.2.551","article-title":"Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug","volume":"84","author":"Beaune P","year":"1987","unstructured":"Beaune P, Dansette PM, Mansuy D, et al.. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci U S A. 1987, 84:551-5. 10.1073\/pnas.84.2.551","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.04.033","article-title":"Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report","volume":"79","author":"Andrade RJ","year":"2023","unstructured":"Andrade RJ, Aithal GP, de Boer YS, et al.. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report. J Hepatol. 2023, 79:853-66. 10.1016\/j.jhep.2023.04.033","journal-title":"J Hepatol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32572","article-title":"Liver injury after SARS-CoV-2 vaccination: features of immune-mediated hepatitis, role of corticosteroid therapy and outcome","volume":"76","author":"Efe C","year":"2022","unstructured":"Efe C, Kulkarni AV, Terziroli Beretta-Piccoli B, et al.. Liver injury after SARS-CoV-2 vaccination: features of immune-mediated hepatitis, role of corticosteroid therapy and outcome. Hepatology. 2022, 76:1576-86. 10.1002\/hep.32572","journal-title":"Hepatology"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","year":"2015","unstructured":"EASL clinical practice guidelines. autoimmune hepatitis. J Hepatol. 2015, 63:971-1004. 10.1016\/j.jhep.2015.06.030","journal-title":"J Hepatol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15724","article-title":"Evaluation of diagnostic and prognostic candidate biomarkers in drug-induced liver injury vs. other forms of acute liver damage","volume":"89","author":"Cueto-S\u00e1nchez A","year":"2023","unstructured":"Cueto-S\u00e1nchez A, Niu H, \u00c1lvarez-\u00c1lvarez I, et al.. Evaluation of diagnostic and prognostic candidate biomarkers in drug-induced liver injury vs. other forms of acute liver damage. Br J Clin Pharmacol. 2023, 89:2497-507. 10.1111\/bcp.15724","journal-title":"Br J Clin Pharmacol"},{"key":"ref51","article-title":"Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature","volume":"20","author":"Eriksson C","year":"2011","unstructured":"Eriksson C, Gustavsson A, Kronvall T, Tysk C. Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature. J Gastrointestin Liver Dis. 2011, 20:77-80.","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/3320325","article-title":"Drug-induced liver injury: clinical evidence of N-Acetyl cysteine protective effects","volume":"2021","author":"Ntamo Y","year":"2021","unstructured":"Ntamo Y, Ziqubu K, Chellan N, et al.. Drug-induced liver injury: clinical evidence of N-Acetyl cysteine protective effects. Oxid Med Cell Longev. 2021, 2021:3320325. 10.1155\/2021\/3320325","journal-title":"Oxid Med Cell Longev"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12437","article-title":"N-acetylcysteine prevents glutathione decrease and does not interfere with paracetamol antinociceptive effect at therapeutic dosage: a randomized double-blind controlled trial in healthy subjects","volume":"33","author":"Pickering G","year":"2019","unstructured":"Pickering G, Macian N, Papet I, Dual\u00e9 C, Coudert C, Pereira B. N-acetylcysteine prevents glutathione decrease and does not interfere with paracetamol antinociceptive effect at therapeutic dosage: a randomized double-blind controlled trial in healthy subjects. Fundam Clin Pharmacol. 2019, 33:303-11. 10.1111\/fcp.12437","journal-title":"Fundam Clin Pharmacol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.07.013","article-title":"Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12\u202fh regimen of N-acetylcysteine for paracetamol overdose (POP trial)","volume":"46","author":"Morrison EE","year":"2019","unstructured":"Morrison EE, Oatey K, Gallagher B, et al.. Principal results of a randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with a 12\u202fh regimen of N-acetylcysteine for paracetamol overdose (POP trial). EBioMedicine. 2019, 46:423-30. 10.1016\/j.ebiom.2019.07.013","journal-title":"EBioMedicine"},{"key":"ref55","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2018.01.040","article-title":"Efficacy of granulocyte colony-stimulating factor and N-acetylcysteine therapies in patients with severe alcoholic hepatitis","volume":"16","author":"Singh V","year":"2018","unstructured":"Singh V, Keisham A, Bhalla A, et al.. Efficacy of granulocyte colony-stimulating factor and N-acetylcysteine therapies in patients with severe alcoholic hepatitis. Clin Gastroenterol Hepatol. 2018, 16:1650-6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.4103\/1319-3767.207711","article-title":"Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: a prospective study","volume":"23","author":"Nabi T","year":"2017","unstructured":"Nabi T, Nabi S, Rafiq N, Shah A. Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: a prospective study. Saudi J Gastroenterol. 2017, 23:169-75. 10.4103\/1319-3767.207711","journal-title":"Saudi J Gastroenterol"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijtb.2022.05.012","article-title":"A study to evaluate the hepatoprotective effect of N- acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life","volume":"70","author":"Sukumaran D","year":"2023","unstructured":"Sukumaran D, Usharani P, Paramjyothi GK, Subbalaxmi MV, Sireesha K, Abid Ali M. A study to evaluate the hepatoprotective effect of N- acetylcysteine on anti tuberculosis drug induced hepatotoxicity and quality of life. Indian J Tuberc. 2023, 70:303-10. 10.1016\/j.ijtb.2022.05.012","journal-title":"Indian J Tuberc"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.15403\/jgld-686","article-title":"Methylprednisolone induced liver injury in a patient with multiple sclerosis","volume":"29","author":"Milovanovic T","year":"2020","unstructured":"Milovanovic T, Jankovic K, Boricic I, Dragasevic S, Stojkovic Lalosevic M, Dumic I. Methylprednisolone induced liver injury in a patient with multiple sclerosis. J Gastrointestin Liver Dis. 2020, 29:119-20. 10.15403\/jgld-686","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v27.i32.5376","article-title":"Immune checkpoint inhibitor-related hepatotoxicity: a review","volume":"27","author":"Remash D","year":"2021","unstructured":"Remash D, Prince DS, McKenzie C, Strasser SI, Kao S, Liu K. Immune checkpoint inhibitor-related hepatotoxicity: a review. World J Gastroenterol. 2021, 27:5376-91. 10.3748\/wjg.v27.i32.5376","journal-title":"World J Gastroenterol"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin J","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al.. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015, 373:23-34. 10.1056\/NEJMoa1504030","journal-title":"N Engl J Med"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1093\/jcag\/gwab019","article-title":"Clinical course and treatment implications of combination immune checkpoint inhibitor-mediated hepatitis: a multicentre cohort","volume":"5","author":"Smith MK","year":"2022","unstructured":"Smith MK, Chan Y, Suo AE, et al.. Clinical course and treatment implications of combination immune checkpoint inhibitor-mediated hepatitis: a multicentre cohort. J Can Assoc Gastroenterol. 2022, 5:39-47. 10.1093\/jcag\/gwab019","journal-title":"J Can Assoc Gastroenterol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(05)70097-0","article-title":"Drug-induced liver disease","volume":"21","author":"Saithanyamurthi H","year":"2017","unstructured":"Saithanyamurthi H, Faust AJ. Drug-induced liver disease. Clin Liver Dis. 2017, 21:21. 10.1016\/S1089-3261(05)70097-0","journal-title":"Clin Liver Dis"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.10.011","article-title":"Long-term sequelae of drug-induced liver injury","volume":"76","author":"Bj\u00f6rnsson ES","year":"2022","unstructured":"Bj\u00f6rnsson ES, Andrade RJ. Long-term sequelae of drug-induced liver injury. J Hepatol. 2022, 76:435-45. 10.1016\/j.jhep.2021.10.011","journal-title":"J Hepatol"},{"key":"ref64","doi-asserted-by":"crossref","DOI":"10.5070\/D31DS9V5Z0","article-title":"Letter: tetracycline-induced hepatotoxicity","volume":"17","author":"Glenn C","year":"2011","unstructured":"Glenn C, Feldman SR. Letter: tetracycline-induced hepatotoxicity. Dermatol Online J. 2011, 17:14.","journal-title":"Dermatol Online J"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2017.1416669","article-title":"Minocycline-associated polyarteritis nodosa and self-limiting hepatitis: a reminder of a potentially re-emerging culprit in drug-induced autoimmune syndromes","volume":"47","author":"Parker M","year":"2018","unstructured":"Parker M, McGill NW. Minocycline-associated polyarteritis nodosa and self-limiting hepatitis: a reminder of a potentially re-emerging culprit in drug-induced autoimmune syndromes. Scand J Rheumatol. 2018, 47:507-8. 10.1080\/03009742.2017.1416669","journal-title":"Scand J Rheumatol"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1111\/jpc.14096","article-title":"Primum non nocere: minocycline-induced liver injury in a teenager","volume":"54","author":"Shankar S","year":"2018","unstructured":"Shankar S, Oliver MR. Primum non nocere: minocycline-induced liver injury in a teenager. J Paediatr Child Health. 2018, 54:1031-3. 10.1111\/jpc.14096","journal-title":"J Paediatr Child Health"},{"key":"ref67","article-title":"Interstitial pneumonia and hepatitis caused by minocycline","volume":"62","author":"Rikken NE","year":"2004","unstructured":"Rikken NE, Klinkhamer PJ, Haak HR. Interstitial pneumonia and hepatitis caused by minocycline. Neth J Med. 2004, 62:","journal-title":"Neth J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/251391-drug-induced-liver-injury-due-to-doxycycline-a-case-report-and-review-of-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,5]],"date-time":"2024-05-05T23:51:21Z","timestamp":1714953081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/251391-drug-induced-liver-injury-due-to-doxycycline-a-case-report-and-review-of-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,5]]},"references-count":67,"URL":"https:\/\/doi.org\/10.7759\/cureus.59687","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,5]]}}}